The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third- or fourth-line treatment in patients with advanced gastric cancer.
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Min-Hee Ryu
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daehwa Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daehwa Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Taiho Pharmaceutical
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; JW Pharmaceutical; Sanofi/Aventis
Consulting or Advisory Role - Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Sun Young Rha
No Relationships to Disclose
 
Seung Tae Kim
No Relationships to Disclose
 
Syma Iqbal
Honoraria - BeiGene
Consulting or Advisory Role - AstraZeneca; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck
 
Jeesun Yoon
No Relationships to Disclose
 
Hyung-Don Kim
No Relationships to Disclose
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeyondBIO; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; SERVIER; TCUBEit
 
Ji-Won Kim
Leadership - Genealogy Care
 
Won Sik Lee
Employment - Idience
Leadership - Idience
 
Min Ju Hong
Employment - Idience
Stock and Other Ownership Interests - Idience
Travel, Accommodations, Expenses - Idience
 
Myongjae Lee
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Eun-Jihn Roh
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
KYOUNG SOO HA
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience